Novartis expects low single-digit drop in 2026 core income To offset patent expiry with $30 billion deals, cancer drugs CFO-designate raises prospect of second-half profit rebound Share price slips ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results